drugset
drugset / Trial / NCT04684485

To Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic Dermatitis

NCT04684485 ↗

Phase 2 Completed 250 enrolled Sun Pharmaceutical Industries, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a Phase II, randomized, double-blind, placebo-controlled study in subjects with moderate to severe atopic dermatitis.

Timeline

Start
2021-07-30
Primary completion
2024-11-11
Completion
2025-03-18

Drugs

EvaluationDrugModalityDoseRoute
Comparator SCD-044 Unknown — —

Indications

atopic eczema